BTK

Oncogene
Tyrosine-protein kinase BTK UniProt accession Q06187

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:19290921). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:19290921). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (PubMed:11606584).

PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK (PubMed:11606584). BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways (PubMed:16517732, PubMed:17932028). Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway (PubMed:16517732).

The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense (PubMed:16517732). Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells (PubMed:16517732, PubMed:17932028). Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation (PubMed:16415872).

BTK also plays a critical role in transcription regulation (PubMed:19290921). Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes (PubMed:19290921). BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B (PubMed:19290921).

Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (PubMed:34554188). Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR (PubMed:9012831). GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression (PubMed:9012831).

ARID3A and NFAT are other transcriptional target of BTK (PubMed:16738337). BTK is required for the formation of functional ARID3A DNA-binding complexes (PubMed:16738337). There is however no evidence that BTK itself binds directly to DNA (PubMed:16738337).

BTK has a dual role in the regulation of apoptosis (PubMed:9751072). Plays a role in STING1-mediated induction of type I interferon (IFN) response by phosphorylating DDX41 (PubMed:25704810)

Source: UniProt

Part of a complex composed of EEIG1, TNFRSF11A/RANK, PLCG2, GAB2, TEC and BTK; complex formation increases in the presence of TNFSF11/RANKL (By similarity). Binds GTF2I through the PH domain. Interacts with SH3BP5 via the SH3 domain.

Interacts with IBTK via its PH domain. Interacts with ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9. Interacts with MPL/TPOR (PubMed:24607955)

Source: UniProt
Cytoplasm, Cell membrane — Peripheral membrane protein, Nucleus, Membrane raft
Source: UniProt

Predominantly expressed in B-lymphocytes

Source: UniProt

The PH domain mediates the binding to inositol polyphosphate and phosphoinositides, leading to its targeting to the plasma membrane. It is extended in the BTK kinase family by a region designated the TH (Tec homology) domain, which consists of about 80 residues preceding the SH3 domain

Source: UniProt
  • X-linked agammaglobulinemia (XLA)

    Humoral immunodeficiency disease which results in developmental defects in the maturation pathway of B-cells. Affected boys have normal levels of pre-B-cells in their bone marrow but virtually no circulating mature B-lymphocytes. This results in a lack of immunoglobulins of all classes and leads to recurrent bacterial infections like otitis, conjunctivitis, dermatitis, sinusitis in the first few years of life, or even some patients present overwhelming sepsis or meningitis, resulting in death in a few hours.

    Treatment in most cases is by infusion of intravenous immunoglobulin.

  • Growth hormone deficiency, isolated, 3, with agammaglobulinemia (IGHD3)

    An X-linked recessive disorder characterized by growth hormone deficiency, short stature, delayed bone age, agammaglobulinemia with markedly reduced numbers of B cells, and good response to treatment with growth hormone.

Source: UniProt
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated Ca+2 mobilization
  • G alpha (q) signalling events
  • G alpha (12/13) signalling events
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • RHO GTPases Activate WASPs and WAVEs
  • G beta:gamma signalling through BTK
  • FCGR3A-mediated phagocytosis
  • Potential therapeutics for SARS
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Source: Reactome via UniProt

Mutations

Cancer Type Mutation Percentage
Central Nervous System Astrocytoma Grade Iv 0.28%
Lung Adenocarcinoma 2.53%
Lung Small Cell Carcinoma 1.48%
Lung Squamous Cell Carcinoma 2.18%
Oesophagus Squamous Cell Carcinoma 0.35%
Pancreas Ductal Carcinoma 0.49%

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to BTK, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 12

NCT ID Condition Brief Title Phase Status
NCT04234061 Mantle Cell Lymphoma Recurrent Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma PHASE2 ACTIVE_NOT_RECRUITING
NCT05048342 Chronic Spontaneous Urticaria A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines PHASE3 COMPLETED
NCT02264574 Chronic Lymphocytic Leukemia, Small-Cell Lymphoma A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) PHASE3 COMPLETED
NCT02824029 Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma PHASE2 COMPLETED
NCT04840602 Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma PHASE2 RECRUITING
NCT05677451 Chronic Spontaneous Urticaria 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up PHASE3 RECRUITING
NCT05640102 Waldenstrom Macroglobulinemia Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia N/A RECRUITING
NCT03891355 Mantle Cell Lymphoma Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL PHASE2 UNKNOWN
NCT03987061 Peripheral Arterial Disease, Critical Limb Ischemia MOTIV Bioresorbable Scaffold in BTK Artery Disease NA UNKNOWN
NCT06524375 Chronic Lymphocytic Leukemia A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period PHASE2 ACTIVE_NOT_RECRUITING